피플
Orum Therapeutics Names Sang-Hyun Lee Head of Research for New DAC Payload
by Sungmin Kim
Dr. Sang-Hyun Lee to Lead Korea Site.."Advancing Next-Generation DAC Payloads and Expanding the Pipeline"
▲Sang-Hyun Lee Vice President, Research Site Head, Korea
Orum Therapeutics announced on the 21th that appointment of Sang Hyun (Shawn) Lee, Ph.D., as Vice President, Research Site Head, Korea. Dr. Lee brings over two decades of scientific leadership in cancer biology and drug discovery, including extensive experience in the discovery and development of protein degrader technologies.
In this role, he will serve as a key bridge between Orum’s research teams in Korea and the U.S. to accelerate progress on the company’s Dual-Precision Targeted Protein Degradation (TPD²®) platform.
“This strategic appointment reflects Orum’s ongoing commitment to building global leadership in TPD-based therapeutics,” said Sung Joo (SJ) Lee, Ph.D., Founder and CEO of Orum Therapeutics. “Dr. Lee’s deep expertise in PROTACs, DACs, and TPD biology will be instrumental as we continue to develop next-generation degrader payload platforms and expand our pipeline.”
“Orum is at the forefront of integrating antibody targeting with protein degrader technology to overcome limitations of traditional therapies. I look forward to working with the team to expand the potential of TPD payloads and help bring transformative therapies to patients.” said Dr. Lee.
Previously, Dr. Lee held senior research leadership roles at Prelude Therapeutics and Arvinas, where he helped advance targeted protein degrader programs. He also held discovery leadership positions at Incyte Corporation and began his research career at Dana-Farber Cancer Institute and Harvard Medical School. Dr. Lee holds a Ph.D. in molecular and cell biology from the University of Texas at Dallas and completed postdoctoral research at Dana-Farber Cancer Institute.
